<DOC>
	<DOCNO>NCT01198782</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy FID 112903 give immediate treatment replacement dry eye subject discontinue least 6 month use RESTASIS .</brief_summary>
	<brief_title>Evaluating Safety Efficacy FID 112903 Post Discontinuation Long-term Use RESTASISÂ® ( Cyclosporine Ophthalmic Emulsion ) 0.05 %</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Patients must least 18 year age Patients must best correct visual acuity 0.6 LogMar good eye , must use Restasis BID least 6 month . Lastly , patient must sodium fluorescein ( NaFl ) corneal stain sum score great equal 3 bad eye . Patients wear contact lens study history hypersensitivity component FID 112903 . Patients ocular intraocular surgery serious ocular trauma within past 6 month , punctal plug type . Patients use prescription topical medication ocular condition ( glaucoma , uveitis , etc ) . Patients use systemic medication may contribute dry eye dose regimen stable least 30 day prior Visit 1 . Patients ocular condition , opinion investigator , preclude safe administration test article . Patients history and/or current evidence following : epithelial herpes simplex keratitis ( dendritic keratitis ) ; vaccinia , active recent varicella viral disease cornea and/or conjunctiva ; active ocular rosacea ; acute chronic bacterial disease cornea and/or conjunctiva and/or eyelid ; mycobacterial infection eye ; and/or fungal disease eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>